MPTP Animal Model of Parkinsonism: Dopamine Cell Death or Only Tyrosine Hydroxylase Impairment? - A Study Using PET Imaging, Autoradiography, and Immunohistochemistry in the Cat

CNS Neuroscience and Therapeutics

Volumn 18, Issue 11, 2012, Pages 934-941

  Aznavour, Nicolas ^a,d   Cendres Bozzi, Christophe ^b   Lemoine, Laetitia ^b   Buda, Colette ^b   Sastre, Jean Pierre ^b   Mincheva, Zoïa ^c   Zimmer, Luc ^a,b   Lin, Jian Sheng ^b  

^a HOSPICES CIVILS DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d EPFL   (Switzerland)

Author keywords

1 methyl 4 phenyl 1,2,3,6 tetrahydropyridine; Autoradiography; Cat; Neurodegeneration; Parkinson's disease; PE2I; Positron emission tomography

Indexed keywords

(3 IODOPRO ENYL) 2BETA 2BETACARBOMETHOXY 3BETA (4' METHYLPHENYL) NORTROPANE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; DOPAMINE TRANSPORTER; NORTROPANE DERIVATIVE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ARTICLE; AUTORADIOGRAPHY; CAT; CELL DEATH; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; MOTOR DYSFUNCTION; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; AUTORADIOGRAPHY; CATS; CELL DEATH; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; TYROSINE 3-MONOOXYGENASE;

EID: 84868149924     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12009     Document Type: Article

References (30)

1. McCormack AL, Thiruchelvam M, Manning-Bog AB, Thiffault C, Langston JW, Cory-Slechta DA, Di Monte D. Environmental risk factors and Parkinson's disease: Selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis 2002;10:119-127.
2. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp Neurol 2006;197:275-283.
3. Henchcliffe C, Beal MF. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 2008;4:600-609.
4. Sonsalla PK, Heikkila RE. The influence of dose and dosing interval on MPTP-induced dopaminergic neurotoxicity in mice. Eur J Pharmacol 1986;129:339-345.
5. Petzinger GM, Langston JW. The MPTP-lesioned nonhuman primate: a model for Parkinson's disease. Scottsdale: Prominent Press, 1998.
6. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem 2001;76:1265-1274.
7. Schneider JS, Markham CH. Neurotoxic Effects of N-Methyl-4-Phenyl-1, 2, 3, 6-Tetrahydropyridine (Mptp) in the Cat - Tyrosine-Hydroxylase Immunohistochemistry. Brain Res 1986;373:258-267.
8. Schneider JS, Yuwiler A, Markham CH. Production of a Parkinson-like syndrome in the cat with N-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): Behavior, histology, and biochemistry. Exp Neurol 1986;91:293-307.
9. Rothblat DS, Schneider JS. Spontaneous functional recovery from Parkinsonism is not due to reinnervation of the dorsal striatum by residual dopaminergic neurons. Brain Res Bull 1994;34:309-312.
10. Schneider JS, Rothblat DS. Neurochemical evaluation of the striatum in symptomatic and recovered MPTP-treated cats. Neuroscience 1991;44:421-429.
11. Rothblat DS, Schneider JS. Repeated exposure to MPTP does not produce a permanent movement disorder in cats recovered from MPTP-induced Parkinsonism. Neurodegeneration 1995;4:87-92.
12. Lin JS, Hou Y, Kitahama K, Jouvet M. Selective suppression of type B monoamine oxidase immunoreactivity in the raphe nuclei following MPTP administration in the cat. NeuroReport 1995;6:321-324.
13. Halldin C, Erixon-Lindroth N, Pauli S, et al. [11C]PE2I - a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003;30:1220-1230.
14. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997;38:1614-1623.
15. Jucaite A, Odano I, Olsson H, Pauli S, Halldin C, Farde L. Quantitative analyses of regional [11C]PE2I binding to the dopamine transporter in the human brain: A PET study. Eur J Nucl Med Mol Imaging 2006;33:657-668.
16. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997;6:279-287.
17. Snyder RSN. A stereotaxic Atlas of the Cat Brain. Chicago: University of Chicago Press, 1961.
18. Lin JS, Hou Y, Sakai K, Jouvet M. Histaminergic descending inputs to the mesopontine tegmentum and their role in the control of cortical activation and wakefulness in the cat. J Neurosci 1996;16:1523-1537.
19. Arnulf I, Crochet S, Buda C, et al. Sleep-wake changes in MPTP-treated cats: An experimental model for studying sleep-wake disorders in Parkinson's disease? Sleep 2005;28:52.
20. Rothblat DS, Schroeder JA, Schneider JS. Tyrosine hydroxylase and dopamine transporter expression in residual dopaminergic neurons: Potential contributors to spontaneous recovery from experimental Parkinsonism. J Neurosci Res 2001;65:254-266.
21. Poyot T, Conde F, Gregoire MC, et al. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and Parkinsonian primates: Comparison with 6-[18F]fluoro-L-dopa. J Cereb Blood Flow Metab 2001;21:782-792.
22. Nagai Y, Obayashi S, Ando K, et al. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 2007;61:809-819.
23. Shetty HU, Zoghbi SS, Liow JS, et al. Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I. Eur J Nucl Med Mol Imaging 2007;34:667-678.
24. Ando K, Maeda J, Inaji M, et al. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced Parkinsonism in common marmosets. Psychopharmacology 2008;195:509-516.
25. DeLorenzo C, Kumar JS, Zanderigo F, Mann JJ, Parsey RV. Modeling considerations for in vivo quantification of the dopamine transporter using [(11)C]PE2I and positron emission tomography. J Cereb Blood Flow Metab 2009;29:1332-1345.
26. Kurosaki R, Muramatsu Y, Watanabe H, Michimata M, Matsubara M, Imai Y, Araki T. Role of dopamine transporter against MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) neurotoxicity in mice. Metab Brain Dis 2003;18:139-146.
27. Rothblat DS, Schneider JS. Regional differences in striatal dopamine uptake and release associated with recovery from MPTP-induced Parkinsonism: An in vivo electrochemical study. J Neurochem 1999;72:724-733.
28. Elsworth JD, Taylor JR, Sladek JR, Collier TJ, Redmond DE, Roth RH. Striatal dopaminergic correlates of stable Parkinsonism and degree of recovery in Old-World primates one year after MPTP treatment. Neuroscience 2000;95:399-408.
29. Wade T, Rothblat DS, Schneider JS. Changes in striatal dopamine D(2) receptors in relation to expression of and recovery from experimental Parkinsonism. Brain Res 2000;871:281-287.
30. Wade TV, Rothblat DS, Schneider JS. Changes in striatal dopamine D3 receptor regulation during expression of and recovery from MPTP-induced Parkinsonism. Brain Res 2001;905:111-119.